Silo Pharma (SILO) Stock Rockets Nearly 50% on European PTSD Patent Approval Signal

Key Highlights

• SILO shares climbed 47.55% during after-hours trading Monday, reaching $0.52
• European Patent Office delivered a Rule 71(3) notice indicating plans to approve a patent for the company’s preventative PTSD therapy
• The intellectual property protects methodologies utilizing serotonin 4 (5-HT4) receptor agonists for preventing stress-related fear and depressive symptoms
• Columbia University exclusively licenses this patent to Silo Pharma, with anticipated coverage spanning key European territories
• The company maintains a market capitalization around $4.98 million, trading significantly below its $1.18 yearly peak

Silo Pharma experienced a significant boost Monday following the European Patent Office’s (EPO) delivery of a Rule 71(3) communication — a procedural indicator that patent approval is forthcoming — for an innovative preventative approach to PTSD treatment.

Silo Pharma, Inc., SILO

The application, designated “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” concentrates on the serotonin 4 (5-HT4) receptor mechanism. This strategy emphasizes blocking stress-triggered fear responses and depressive symptoms proactively, distinguishing itself from conventional post-symptom treatments.

Columbia University holds the original patent rights and has granted Silo Pharma exclusive licensing privileges. The biotechnology firm is currently assessing Unitary Patent safeguards alongside individual country validations throughout Europe to maximize territorial reach.

CEO Eric Weisblum characterized the development as a “significant achievement” that bolsters the firm’s worldwide intellectual property portfolio.

Patent Scope and Applications

The approved claims encompass therapeutic protocols designed to prevent stress-triggered fear reactions, depressive behaviors, and associated mood disorders through specific 5-HT4 receptor agonist compounds.

This represents a paradigm shift from conventional PTSD interventions, which primarily address established symptoms. Silo’s methodology concentrates on enhancing stress tolerance before traumatic exposure occurs.

The intellectual property directly underpins SPC-15, Silo’s flagship PTSD development program. The company’s therapeutic portfolio extends to SP-26 for fibromyalgia and chronic pain management, plus early-stage candidates addressing Alzheimer’s disease.

Stock Performance Analysis

SILO concluded Monday’s standard trading session at $0.36 before surging to $0.52 during extended hours — representing a 47.55% advance.

The yearly trading range illustrates the stock’s volatility: shares peaked at $1.18 and bottomed at $0.22 throughout the past twelve months. This substantial fluctuation characterizes a company valued at approximately $5 million.

Benzinga’s equity assessment indicated SILO displayed unfavorable price momentum across multiple timeframes prior to Monday’s announcement.

The after-market rally pushed shares above the $0.50 threshold for the first time in recent weeks, although the price remains well below its annual high.

Once officially finalized, the EPO patent grant should provide Silo’s preventative PTSD therapy with comprehensive protection throughout principal European jurisdictions.